Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs by its US subsidiary, Glenmark Therapeutics Inc., in the US market.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of the Company shall be closed for the Designated Persons from October 01, 2026, and remain closed till the declaration of Unaudited Financial Results (Standalone and Consolidated) of the Company for the Second Quarter ended September 30, 2026, and forty-eight hours thereafter.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the Exchange about the schedule of an Analyst/ Institutional Investor meeting to be conducted on 29-09-2026 at PL Capital - Emerging Titans Mumbai Physical Both 2026 Conference.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited held its 48th Annual General Meeting on September 11, 2026, through Video Conferencing. The meeting was attended by 54 shareholders, and the requisite quorum was present. The company secretary and compliance officer provided general instructions regarding participation at the meeting. The chairman delivered a speech, and the members were informed about the statutory auditors' report and the secretarial audit report. The resolutions put forth at the meeting were related to the audited standalone financial statements and the audited consolidated financial statements.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals' bank loans have been upgraded to 'IND AA+' by India Ratings and Research, with a stable outlook, due to improved financial visibility and a strong credit profile.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package, achieving annual sales of approximately $69.9 million.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has received U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray. The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the Exchange about a copy of a newspaper publication regarding the 48th Annual General Meeting to be held on September 11, 2026, through Video Conferencing or Other Audio-Visual Means.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited sent letters to shareholders whose email addresses are not registered, providing a web link to access the Integrated Annual Report and Annual General Meeting Notice for FY 2025-26.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has entered into a settlement agreement with Humana for $15.28 million to resolve antitrust and consumer protection lawsuits in the US. The company denies any wrongdoing and the settlement does not constitute an admission of liability.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has allotted 23,863 equity shares under the Employee Stock Option Plan 2016 to the grantee who had exercised the options. The paid-up capital of the company has increased from Rs. 28,22,00,809 to Rs. 28,22,24,672.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the Exchange about the schedule of analyst/institutional investor meetings to be conducted in August and September 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication regarding the 48th Annual General Meeting to be held through Video Conferencing/OAVM on September 11, 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the transcript of the Earnings Call held on August 3, 2026, for the quarter ended June 30, 2026, which has been uploaded on the Company's website.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has uploaded the audio recording of its Q1 FY 2026-27 earnings call on its website.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in accordance with SEBI regulations.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investor Presentation' for Q1 FY 27, with consolidated revenue of Rs. 40,185 million, a 23.1% YoY growth, and EBITDA of Rs. 8,048 million with a margin of 20.03%. The company has reported strong growth across its key markets, with India business growth of 15.5%, North America core business growth of 19.8%, and Emerging Markets business growth of 27.7%. The results reinforce the direction of Glenmark's next phase: strengthening its core businesses while expanding its differentiated specialty and innovation-led platforms.